Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 18/20 | 0.55 |
| ▸ | DDB1 | Q16531 | 10/20 | 0.55 |
| ▸ | GSPT1 | P15170 | 8/20 | 0.55 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.55 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1413703 | 0.92 | CRBN (0.47) | CRBNDDB1GSPT1IKZF3CSNK1A1 | |
| SCHEMBL1413534 | 0.92 | CRBN (0.47) | CRBNDDB1GSPT1IKZF3CSNK1A1 | |
| SCHEMBL1413476 | 0.92 | CRBN (0.51) | CRBNDDB1GSPT1IKZF3CSNK1A1 | |
| SCHEMBL19808762 | 0.91 | CRBN (0.47) | CRBNDDB1GSPT1IKZF3CSNK1A1 | |
| Hydrochloric Acid SCHEMBL62088 | 0.91 | CRBN (0.50) | CRBNDDB1GSPT1IKZF3CSNK1A1 | |
| SCHEMBL1413575 | 0.90 | CRBN (0.50) | CRBNDDB1GSPT1IKZF3CSNK1A1 | |
| SCHEMBL1413669 | 0.90 | CRBN (0.46) | CRBNDDB1GSPT1IKZF3CSNK1A1 | |
| SCHEMBL1413611 | 0.88 | CRBN (0.48) | CRBNDDB1GSPT1IKZF3CSNK1A1 | |
| SCHEMBL1413716 | 0.88 | CRBN (0.48) | CRBNDDB1GSPT1IKZF3CSNK1A1 | |
| SCHEMBL1413710 | 0.87 | CRBN (0.44) | CRBNDDB1GSPT1IKZF3CSNK1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11733233-B2 | Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases | CELGENE CORPORATION (US) | 2023-08-22 | — | — | US | disclosed |
| US-11419861-B2 | Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases | CELGENE CORPORATION (US) | 2022-08-23 | — | — | US | disclosed |
| US-20210000813-A1 | COMPOSITIONS AND METHODS FOR INDUCING CONFORMATIONAL CHANGES IN CEREBLON AND OTHER E3 UBIQUITIN LIGASES | CELGENE CORPORATION (US) | 2021-01-07 | — | — | US | disclosed |
| US-20210003557-A1 | COMPOSITIONS AND METHODS FOR INDUCING CONFORMATIONAL CHANGES IN CEREBLON AND OTHER E3 UBIQUITIN LIGASES | CELGENE CORPORATION (US) | 2021-01-07 | — | — | US | disclosed |
| EP-3160486-B1 | COMPOSITIONS AND METHODS FOR INDUCING CONFORMATIONAL CHANGES IN CEREBLON OTHER E3 UBIQUITIN LIGASES | CELGENE CORP (US) | 2020-11-18 | — | — | EP | disclosed |
| US-10830762-B2 | Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases | CELGENE CORPORATION (US) | 2020-11-10 | — | — | US | disclosed |
| US-10668057-B2 | Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases | CELGENE CORPORATION (US) | 2020-06-02 | — | — | US | disclosed |
| CN-107739389-B | 3-substituted (1-oxoisoindoline-2-yl) piperidine-2, 6-diketone compound and synthetic method thereof | 华东师范大学 | 2020-03-31 | — | — | CN | disclosed |
| EP-3327013-B1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CELGENE CORP (US) | 2019-04-24 | — | — | EP | disclosed |
| US-20190030019-A1 | COMPOSITIONS AND METHODS FOR INDUCING CONFORMATIONAL CHANGES IN CEREBLON AND OTHER E3 UBIQUITIN LIGASES | CELGENE CORPORATION | 2019-01-31 | — | — | US | disclosed |
| US-20120252843-A1 | ISOINDOLINE COMPOUNDS AND METHODS OF THEIR USE | CELGENE CORPORATION | 2012-10-04 | — | — | US | disclosed |
| US-8222249-B2 | Isoindoline compounds and methods of their use | CELGENE CORPORATION (US) | 2012-07-17 | — | — | US | disclosed |
| US-20120122865-A1 | ISOINDOLINE COMPOUNDS AND METHODS OF THEIR USE | CELGENE CORPORATION | 2012-05-17 | — | — | US | disclosed |
| US-8129375-B2 | Isoindoline compounds and methods of their use | CELGENE CORPORATION (US) | 2012-03-06 | — | — | US | disclosed |
| EP-2358697-A1 | Isoindoline compounds for use in the treatment of cancer | CELGENE CORPORATION (US) | 2011-08-24 | — | — | EP | disclosed |
| EP-2291365-A1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CELGENE CORPORATION (US) | 2011-03-09 | — | — | EP | disclosed |
| US-20100204227-A1 | ISOINDOLINE COMPOUNDS AND METHODS OF THEIR USE | CELGENE CORPORATION | 2010-08-12 | — | — | US | disclosed |
| WO-2010053732-A1 | ISOINDOLINE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | CELGENE CORPORATION (US) | 2010-05-14 | — | — | WO | disclosed |
| WO-2009145899-A1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CELGENE CORPORATION (US) | 2009-12-03 | — | — | WO | disclosed |
| US-20090142297-A1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CELGENE CORPORATION | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10668057-B2 | Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases | CRBN, UBQLN1, UBQLN2 | CRBN 1/4885DDB1 247/4885GSPT1 1479/4885 |
| US-20100204227-A1 | ISOINDOLINE COMPOUNDS AND METHODS OF THEIR USE | CPT1A, CYP11B2, NPC1 | CRBN 4221/4885DDB1 1898/4885GSPT1 2532/4885 |
| US-20120252843-A1 | ISOINDOLINE COMPOUNDS AND METHODS OF THEIR USE | CPT1A, CYP11B2, NPC1 | CRBN 4221/4885DDB1 1898/4885GSPT1 2532/4885 |
| US-11419861-B2 | Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases | CRBN, UBQLN1, UBQLN2 | CRBN 1/4885DDB1 247/4885GSPT1 1479/4885 |
| US-20120122865-A1 | ISOINDOLINE COMPOUNDS AND METHODS OF THEIR USE | CPT1A, CYP11B2, NPC1 | CRBN 4221/4885DDB1 1898/4885GSPT1 2532/4885 |
| US-20210003557-A1 | COMPOSITIONS AND METHODS FOR INDUCING CONFORMATIONAL CHANGES IN CEREBLON AND OTHER E3 UBIQUITIN LIGASES | CRBN, UBQLN1, UBQLN2 | CRBN 1/4885DDB1 247/4885GSPT1 1479/4885 |
| US-20090142297-A1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CYP3A5, CYP3A7, CYP3A4 | CRBN 4610/4885DDB1 3649/4885GSPT1 1959/4885 |
| US-20190030019-A1 | COMPOSITIONS AND METHODS FOR INDUCING CONFORMATIONAL CHANGES IN CEREBLON AND OTHER E3 UBIQUITIN LIGASES | CRBN, UBQLN1, UBQLN2 | CRBN 1/4885DDB1 247/4885GSPT1 1479/4885 |
| US-20210000813-A1 | COMPOSITIONS AND METHODS FOR INDUCING CONFORMATIONAL CHANGES IN CEREBLON AND OTHER E3 UBIQUITIN LIGASES | CRBN, UBQLN1, UBQLN2 | CRBN 1/4885DDB1 247/4885GSPT1 1479/4885 |
| US-11733233-B2 | Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases | CRBN, UBQLN1, UBQLN2 | CRBN 1/4885DDB1 247/4885GSPT1 1479/4885 |
| US-10830762-B2 | Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases | CRBN, UBQLN1, UBQLN2 | CRBN 1/4885DDB1 247/4885GSPT1 1479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.